Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Michael J Reardon Added: 1 year ago
ACC 2025 - EVOLUT Low-Risk findings show the Medtronic TAVR system is a safe and effective treatment for aortic stenosis vs surgical valves at five years.Dr Michael Reardon (Houston Methodist, Texas, US) joins us onsite at ACC to discuss the EVOLUT Low Risk trial (NCT02701283; Medtronic Cardiovascular), investigating the safety and effectiveness of the Medtronic TAVR system compared to surgical… View more
Author(s): Richard Pratley Added: 1 year ago
EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial.Interview Questions:1. What is the reasoning behind the FLOW Trial?2. What was the patient population and study design?3. What are the key results?4. Were there any surprising or unexpected findings?5. What further… View more
Author(s): Vlado Perkovic Added: 1 year ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median… View more
Author(s): Samineh Sehatbakhsh Added: 8 months ago
Explore comprehensive lifetime management strategies for aortic stenosis with Dr Samineh Sehatbakhsh, addressing the evolving landscape of treatment options for patients across all risk categories.This detailed presentation, part of the Complex Cases track, examines the critical decision-making process between TAVR and surgical aortic valve replacement in the modern era. Dr Sehatbakhsh addresses… View more
Author(s): Harriette Van Spall , Added: 1 year ago
AHA Conference 2024 — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD).The FLOW trial (NCT03819153) is designed to assess the effect of… View more
Author(s): Ole De Backer Added: 1 year ago
EuroPCR 24 - We are joined onsite by Prof Ole De Backer (Rigshospitalet, DK) to discuss the findings from the NOTION-2 Study. (NCT02825134).NOTION-2 is a randomized, multicenter trial which aimed to investigate transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in 376 patients under 75 years of age with severe aortic valve stenosis in regard to intra-… View more
Author(s): Nicole Karam Added: 9 months ago
Discover the sex-specific challenges in aortic stenosis diagnosis and management with Prof Nicole Karam (European Hospital Georges Pompidou, Paris, FR).This presentation, part of a comprehensive two-part series on complex cases in interventional cardiology, explores the critical pathophysiological differences between men and women that impact diagnostic approaches and therapeutic decision-making… View more
Author(s): Yassir Javaid, Michel Burnier, Mariya Tokmakova ,et al Start date: Jun 25, 2025
Join an expert panel of internationally recognised cardiovascular specialists for a CME-accredited* webinar on the latest strategies in hypertension management for patients with cardiovascular disease. Chaired by Dr Yassir Javaid (Imperial College Healthcare NHS Trust, London, UK), with Prof Michel Burnier (University Hospital of Lausanne, Lausanne, CH) Prof Mariya Tokmakova (Medical University… View more
Added: 2 months ago Source:  Transcatheter Academy
Seven-year follow-up data from the PARTNER 3 trial shows no significant difference in key outcomes between transcatheter aortic-valve replacement (TAVR) and surgical aortic-valve replacement (SAVR) for low-risk patients with severe, symptomatic aortic stenosis.¹ This long-term assessment provides further insight into valve durability and clinical outcomes, building on previous 5-year data which… View more
Author(s): Nicolas M Van Mieghem Added: 1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter aortic valve replacement (TAVR) in addition to optimal heart failure therapy (OHFT) compared to OHFT alone in patients with heart failure and moderate aortic stenosis.Dr Nicolas M Van Mieghem (Erasmus University Medical Center, Rotterdam, NL) joins us onsite at TCT Conference to discuss the findings from TAVR UNLOAD (NCT02661451)… View more